Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma

Atta, M. M.; El‐Masry, Samir; Abdelhameed, Mohamed; Baiomy, Hosam; Ramadan, Naglaa E.

doi:10.1016/j.clinbiochem.2008.06.006

Cited by 32 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p53 Ab levels are elevated in 13-47% of preoperative CRC patients [5,6,7,8,9,10], as well as in patients with other solid tumors, such as in 11.2-32% of gastric cancer patients [12,16,17,18], 13.2-21.5% of breast cancer patients [34,35,36], 8-30% of lung cancer patients [13,19,20,21,22], and 7-32% of hepatocellular carcinoma patients [15,24,25,26,27]. In the present study, the percentage of CRC patients with p53 Ab elevation was 26.3%, corroborating previous reports (table 1).…”

Section: Discussionmentioning

confidence: 99%

“…p53 Ab production is associated with TP53 gene mutation in CRC tissue and the consequent accumulation of mutant TP53 protein. The p53 Ab can be found in 13-47% of CRC patients [5,6,7,8,9,10], and its elevation has been reported in a wide variety of solid cancers such as esophageal, gastric, lung, ovarian, and hepatocellular cancers [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27]. Thus, the clinical applicability of the p53 Ab in cancer screening is well established.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

Abe

Kawai²,

Ishihara³

et al. 2016

Oncology

View full text Add to dashboard Cite

Objective: To determine the utility of the post-/preoperative anti-p53 antibody (p53 Ab) ratio as a prognostic factor for colorectal cancer (CRC) recurrence. Methods: A total of 737 nonmetastatic CRC patients who had undergone R0 resection were retrospectively analyzed. p53 Ab levels were measured within 1 month prior to and at least every 3 months after surgery. Post-/preoperative p53 Ab ratios were calculated, and the optimal ratio cutoff values for predicting recurrence were determined using the Kaplan-Meier method and the log-rank test. Results: Preoperative p53 Ab elevation was observed in 194 patients (pre-p53 high). Preoperative p53 Ab levels correlated with TNM stage. Re-elevation of p53 Ab levels occurred on recurrence in the pre-p53 high group, but not in the pre-p53 low group (n = 543). In the pre-p53 high group, patients who experienced tumor recurrence exhibited a slow postoperative reduction of p53 Ab levels, and a post-/preoperative p53 Ab ratio >0.4 at postoperative 3 months predicted relapse-free survival. In other words, a p53 Ab level remaining higher than 40% of the preoperative level was an independent and strong risk factor for recurrence in multivariate analyses. Conclusion: In CRC patients with preoperative p53 Ab elevation, the rate of p53 Ab reduction in the early postsurgical period is a promising prognostic factor for recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

Abe

Kawai²,

Ishihara³

et al. 2016

Oncology

View full text Add to dashboard Cite

show abstract

“…8 To date, some studies have documented that p53 alterations are correlated with tumour differentiation, vascular invasion, tumour stage, Child-Pugh class and serum AFP in HCC. 9–12 However, the prognostic significance of p53 alterations in HCC has not been concluded as clinical evidence. Some prognostic studies suggested that tumour p53 upregulation and serum anti-p53 antibody elevation were associated with recurrence-free survival (RFS) and OS in HCC patients 12–16 while the similar results were not confirmed in other studies.…”

Section: Introductionmentioning

confidence: 99%

“…9–12 However, the prognostic significance of p53 alterations in HCC has not been concluded as clinical evidence. Some prognostic studies suggested that tumour p53 upregulation and serum anti-p53 antibody elevation were associated with recurrence-free survival (RFS) and OS in HCC patients 12–16 while the similar results were not confirmed in other studies. 17–21 Furthermore, most of studies supported that HCC patients with mutant p53 phenotype had poor survival, but the prognostic effect fluctuated with a wide range of hazard ratios (HRs) (1.98 to 13.88) due to small and heterogeneous studies.…”

Section: Introductionmentioning

confidence: 99%

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis

Liu

Zhang

et al. 2012

European Journal of Cancer

111

View full text Add to dashboard Cite

Background The prognostic significance of p53 aberration in hepatocellular carcinoma (HCC) remains inconclusive. This review aimed to provide comprehensive evidence on the association of p53 alterations with recurrence-free survival (RFS) and overall survival (OS) in HCC patients. Methods Systematic literature searches were conducted until July 2010. Meta-analysis was performed to estimate prognostic effects of p53 alterations on patient outcomes in HCC. Sensitivity and subgroup analyses were also conducted in the meta-analysis. Results Thirty-seven studies (7 tumour p53 mutation, 23 tumour p53 expression and 7 serum anti-p53 antibodies) were included in the systematic review. The average percentages of p53 mutation, p53 expression upregulation and anti-p53 antibody level elevation in HCC patients were 31.5%, 35.0% and 23.8%, respectively. Tumour p53 alterations were associated significantly with poor patient outcomes in HCC: the summary hazard ratio (HR) of mutant p53 versus wild type p53 phenotype was 2.58 [95% confidence interval (CI): 1.96–3.41] for OS and 3.19 [95% CI: 2.21–4.60] for RFS, respectively; and the summary HR of upregulated p53 expression versus low/undetectable p53 expression was 1.68 [95% CI: 1.49–1.90] for OS and 1.89 [95% CI: 1.34–2.66] for RFS, respectively. However, elevated serum anti-p53 antibody was only associated with poor OS in HCC group with high propotion (≥50%) of hepatitis C virus (HCV) infection [HR: 1.92; 95% CI: 1.30–2.85]. Moreover, sensitivity analyses showed that the results of meta-analyses were not altered. Conclusion HCC patients with p53 mutation and upregulated expression in tumour tissue have a shorter OS and RFS than patients with wild type p53 and low/undetectable p53 expression. However, the prognostic value of serum anti-p53 antibody is required to be further examined.

show abstract

“…Anti-p53 antibodies were evaluated by a modified ELISA test (Atta et al 2008) to estimate the levels in sera of HCC patients and control groups, as a modification of Engvall and Perlmann (1971). …”

Section: Methodsmentioning

confidence: 99%

Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma

et al. 2013

View full text Add to dashboard Cite

The rate of hepatocellular carcinoma (HCC) is increasing worldwide including Egypt. Non-B non-C HCC was reported in some countries. We aimed to investigate P53 antibodies and alpha-fetoprotein in patients with non-B non-C HCC in our region. In a case series study, included 281 patients with HCC and 20 patients with liver cirrhosis of matched age, sex and social factors were received for management at Tanta University Hospitals. Sera were tested for HCV and HBV markers by ELISA/PCR, alpha-fetoprotein (AFP) level and anti-p53 antibody were evaluated by ELISA. Antinuclear antibody, serum copper and iron were assessed in non-viral HCC. Liver scanning and biopsy were evaluated. Non-B non-C HCC patients were 13.87% of total. P53 antibody serum level in non-B non-C HCC patients showed insignificant difference (p>0.05) as compared to viral-associated HCC, while significant as compared to cirrhosis. They had significant decrease in serum AFP level (p<0.001) as compared to viral-associated HCC. Their tumors were mainly solitary, and have smaller-sizes. Sensitivity, specificity, PPV, NPV and accuracy test of anti P53 antibody positive patients were 91.52%, 84.63%, 90.34%, 80.2% and 74.8% respectively. It correlates positively with AFP, tumor size and staging, MELD score and Child-Pugh score.Non-B non-C HCC showed high serum prevalence of anti-p53 as viral-associated HCC suggesting an evidence of high onchogenecity. It appears of much benefit in diagnosis, follow up and differentiation from cirrhosis in presence of low levels of alpha-fetoprotein.

show abstract

Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma

Cited by 32 publications

References 17 publications

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis

Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma

Contact Info

Product

Resources

About